newsfilter
← Latest News
ACCESS Newswire·

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026

  • Protagonist Therapeutics announced that President & CEO Dinesh V. Patel, Ph.D. will participate in two investment bank conferences in September 2026.
  • The company will attend the Citi Biopharma Back to School Conference in New York on September 9, 2026, at 10:40 A.M. ET via fireside chat.
  • The company will attend the 2026 Cantor Global Healthcare Conference in New York on September 10, 2026, at 10:20 A.M. ET via fireside chat.
  • Webcasts for both presentations are available online, with replays accessible on the Investor Relations webpage for one year.
  • Protagonist has two FDA-approved medicines: ICOTYDE (icotrokinra) licensed to Johnson & Johnson for plaque psoriasis, launched in the U.S. in March 2026; MIMRYLO (rusfertide) licensed to Takeda for erythrocytosis in polycythemia vera.
  • ICOTYDE is in Phase 3 development for psoriatic arthritis, ulcerative colitis, and Crohn's disease.
  • The company maintains a pipeline including oral IL-17 antagonist peptides, anti-obesity dual & triple agonists, oral hepcidin functional mimetics, and new IL-4 and amylin discovery programs.